Parkinson's Study Probes Link to Ashkenazi Mutation

A study sponsored by The Michael J. Fox Foundation for Parkinson’s Research will investigate a genetic mutation found more often in Ashkenazi Jews.

The Parkinson’s Progression Markers Initiative, a large-scale biomarker study, is expanding to study individuals with genetic mutations associated with Parkinson’s disease.

Among those mutations is the LRRK2, which accounts for a greater number of Parkinson’s cases among certain ethnic populations and families, notably Jews of Eastern European descent.

The study will enroll 250 people with the LRRK2 mutation and Parkinson’s and a like number with the mutation but without Parkinson’s.

Genetic mutations account for 5 percent to 10 percent of all Parkinson’s cases, but a study of these individuals may reveal disease traits that apply to all Parkinson’s patients.

The Fox Foundation has secured 15 industry partners and co-funding sponsors for the initiative. They include Abbott Laboratories, Biogen, BMS, Covance, Eli Lilly, GE Healthcare, Genentech, GSK, Merck, Pfizer and Roche.

The study will take place at 32 clinical sites around the world.

Written by


Your Comments

The Forward welcomes reader comments in order to promote thoughtful discussion on issues of importance to the Jewish community. In the interest of maintaining a civil forum, The Forward requires that all commenters be appropriately respectful toward our writers, other commenters and the subjects of the articles. Vigorous debate and reasoned critique are welcome; name-calling and personal invective are not and will be deleted. Egregious commenters will be banned from commenting. While we generally do not seek to edit or actively moderate comments, our spam filter prevents most links and certain key words from being posted and the Forward reserves the right to remove comments for any reason.

Recommend this article

Parkinson's Study Probes Link to Ashkenazi Mutation

Thank you!

This article has been sent!